The United Arab Emirates has achieved a global milestone by becoming the first country to authorize an oral medication for the treatment of non-segmental vitiligo. This regulatory decision provides a new therapeutic pathway for patients aged 12 and older who require systemic therapy to manage the condition.
The Emirates Drug Establishment (EDE) granted approval for the use of RINVOQ, known generically as upadacitinib, specifically for adolescents and adults whose vitiligo necessitates systemic treatment that circulates throughout the body. This once-daily oral medication represents a significant addition to the current range of available therapies, which traditionally include topical applications, phototherapy, and laser-based interventions.
Vitiligo is a non-contagious skin disorder characterized by the loss of pigment, which results in the development of white patches. The condition arises when melanocytes—the cells responsible for melanin production—are destroyed. While the precise cause remains unknown, medical experts generally identify an autoimmune response as a primary contributing factor. Because the condition can manifest differently across various skin tones and may be confused with other dermatological issues, the EDE emphasizes the importance of professional medical assessment for an accurate diagnosis.
The EDE stated that this approval underscores the nation’s commitment to maintaining an advanced regulatory framework capable of responding to rapid global scientific advancements. By integrating such innovative treatments into the local pharmaceutical sector, the UAE aims to improve patient access to modern medical solutions. Health authorities have further advised individuals who observe unusual changes in their skin pigmentation to seek consultation with a specialist, as early diagnosis is essential for determining the most effective and appropriate treatment plan for each patient. The report also notes that giving eligible patients aged 12 and above a new treatment option, uAE has become the first country in the world to approve an oral treatment for non-segmental vitiligo. The report also notes that although an autoimmune response is considered one of the main factors, the exact cause is not fully understood. The report also notes that stay up to date with the latest news.
Source: Khaleej Times
